Interview: António Portela, CEO, Bial Portugal
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Founded in 1924, BIAL is today the biggest Portuguese pharmaceutical group with a team of about 900 collaborators, and with a strong commitment to R&D, internationalization and quality.
BIAL is also an international pharmaceutical group with business activities in more than 50 countries. Based in Portugal, Bial owns facilities in Spain—where a production unit and a R&D centre dedicated to allergic immunotherapy are situated—Italy, Mozambique, Panama, and other countries.
Strongly committed to therapeutic innovation, investing more than 20 percent of its turnover in R&D every year, BIAL Group has launched the first drug of Portuguese patent, an anti-epileptic. Available since 2009 in several European markets, under the brand Zebinix, this antiepileptic, eslicarbazepine acetate, has recently been approved by the regulator of the pharmaceutical market in the US, Food and Drug Administration (FDA), for commercialization in the United States under the brand Aptiom.
BIAL has also a second pharmaceutical for its own research, for the treatment of the Parkinson disease, which is already in an advanced development process (phase III of clinical development).
The company expects to introduce more new medicines and vaccines to the market in the next years, specifically in the central nervous system, the cardiovascular system and allergen immunotherapy, which will be an added impetus to its international expansion.
Since 2005 the Bial Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA), which has recognized Bial as a research and development pharmaceutical company capable of bringing new medicines to the world to improve human health and the quality of life of the populations.
Bial Group has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award and Scientific Research Grants, well recognized worldwide.
Bial Contact Info:
À Av. da Siderurgia Nacional
4745-457 S. Mamede do Coronado – Portugal
Phone: +351 22986 6100 | Fax: +351 22986 6190
www.bial.com | info@bial.com
António Portela, CEO of Portugal’s flagship pharmaceutical company Bial, talks about the recent approval of Aptiom by the FDA, the first Portuguese drug to ever to be approved in the…
Women account for half of the Portuguese labour force, but Portugal lags behind the European average for women in top positions, as a 2023 McKinsey study shows. However, Portuguese pharma…
Diabetes is a rising threat to the Portuguese people, the country’s healthcare system, and its economy. Portugal’s National Diabetes Observatory observed that 1.1 million Portuguese people between the ages of…
Novo Nordisk’s spectacular ascendancy in 2023 has meant that its country managers across the world have had to embrace scrutiny and press coverage like never before. In its centenary…
Luis Abrantes explains how Generis, as one of the leading companies by volume in both the retail and hospital segments of the Portuguese pharma market, serves a huge number of…
Azevedos Group’s João Sotana outlines the firm’s diverse strategic pillars, including manufacturing for Portugal and international markets; its focus on sustainability and innovation; and how it plans to stay ahead…
After achieving the highest sales figures in the affiliate’s history in 2023, general manager of Teva Pharmaceuticals Portugal Marta Gonzalez Casal outlines the restructuring efforts that have taken place in…
While not a major player in clinical trials at the European level, Portugal has untapped potential in this field, leveraging a first pioneering centre in Braga, the country’s strong scientific…
Monica Bettencourt-Dias of the Gulbenkian Institute for Science highlights the IGC’s pioneering role in biological sciences, supporting scientists and innovators who have significantly contributed to the field globally for over…
Alberto Navia-Osorio Pascual enthusiastically describes how Viatris has established itself as the leading pharmaceutical company in Portugal, leveraging the strengths of its integrated portfolios. The company has focused on brand…
Paula Barriga, VP & GM at Novo Nordisk Portugal, discusses the high prevalence of obesity, which affects over two million people in a country where none of the available pharmacological…
The Portuguese Association of Hospital Pharmacists (APFH) is dedicated to the education and training of over 1000 hospital pharmacists; essential members of the multidisciplinary teams needed to tackle serious illnesses…
João Rito introduces Bluebio Alliance, a Portuguese association focusing on bio-based marine resources and their sustainable utilisation. Rito’s work involves extensive collaboration across sectors, including pharmaceuticals, to promote the blue…
See our Cookie Privacy Policy Here
